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Measles virus (MV) is a potentially eradicable disease that
still ranks as one of the leading causes of infectious disease-
induced morbidity and mortality in childhood in the world.
Currently, 30–40 million measles infections occur world-
wide each year leading to 1–2 million deaths (Manchester
et al., 2000). In addition to causing an acute respiratory
infection, measles is also associated with a serious, but tran-
sient suppression of cell-mediated immunity. This
immunosuppression can lead to secondary infections, and
major complications such as pneumonia and diarrhoea in
children. In rare cases, it can also cause encephalitis and
persistent central nervous system infections (Griffin &
Bellini, 1996). There are highly effective vaccines available,
although their safety has occasionally been questioned
because of tenuous links to Crohn disease and particularly
to autism (Kawashima et al., 2000). However, no studies to
date have conclusively established a causal relationship with
vaccine viruses and these two diseases (Afzal et al., 2000).
Although the use of a live attenuated virus has nearly
eradicated the endemic circulation of measles in the USA,
reintroduction of the virus can cause repeated limited out-
breaks (Gay, 2000). Therefore, campaigns need to be main-
tained that establish high routine coverage of the vaccine to
prevent the reaccumulation of susceptible hosts that will
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Despite intense efforts to increase vaccine cover-
age, measles virus (MV) still causes significant
morbidity and mortality in the world, sometimes
as the result of severe, chronic, lethal disease. In
an effort to develop therapies to supplement
immunization strategies, a number of 5′-nor car-
bocyclic adenosine analogues were evaluated for
anti-MV activity in CV-1 monkey kidney cells. Of
those compounds tested, those either unsubstitut-
ed at C4 or possessing a hydroxyl, azido or amino
substituent at that position were the most active,
with particularly significant inhibition of MV,
strain Chicago-1. The EC50 values against this strain
ranged from <0.1 to 1 mg/ml, as determined by
cytopathic effect reduction assay, and confirmed
by neutral red uptake. By virus yield reduction
assay (+)-(1S,2S,3R,4S)-4-(6′-amino-9′H-purin-9′-
yl)cyclopentane-1,2,3-triol (2) (–)-(1R,2S,3R)-1-(6′-
amino-9′H-purin-9′-yl)-2,3-dihydoxycyclopent-4-
ene (3) (–)-(1R,2S,3R)-1-(6′-amino-9′H-purin-9′-
yl)cyclopentane-2,3-dihydoxycyclopentane (5) and
(–)-(1R,2R,3R,4S)-4-amino-1-(6′-amino-9′H-purin-9′-
yl)cyclopentane-2,3-diol (8) were the most potent
compounds tested, all with EC90 values of ≤0.4
mg/ml. Compounds 3 and 5 were also tested
against other MV strains, and similarly inhibited
those strains except for four designated as Bil,
Edmonston, SA and X-1108. Compound 8 did not
potently inhibit these other MV strains. In addi-
tion, 3, 5 and 8 demonstrated synergistic (addi-
tive) inhibition of MV replication in combination
with ribavirin at several concentrations.
Compounds 3, 5 and 8 were also potent MV
inhibitors even when added to infected cells 24 h
after virus exposure. None of these three com-
pounds was virucidal at concentrations that inhib-
ited viral replication as determined by virus yield
reduction assay. Most compounds tested were
also not toxic at concentrations >100 mg/ml in
actively growing and stationary-phase cells.
Results suggest that these compounds may be
clinically useful anti-MV virus agents.
Keywords: 5’-norcarbocyclic, adenosine analogue,
measles virus, inhibition, antiviral, structure activ-
ity relationships
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permit sustained measles transmission (Gay, 2000). Those
who may be especially vulnerable are the non-immunized
or immunized individuals with waning immunity, such as
those living in extended care facilities (Clements & Cutts,
1995). In addition, with an increasing number of health
care professionals having only received vaccine or never
having been exposed to measles infection in infancy, noso-
comially-acquired and -transmitted MV infections in
health-care facilities may also contribute to a potential
increase in MV infections (Steingart et al., 1999). Thus,
the potential for limited measles outbreaks always exists
until indigenous virus transmission is eliminated in most
populations of a given country (reviewed by De Serres et
al., 2000)
Of significance for the elimination of MV outbreaks is
that virus isolates are not of single genotype or even
serotype. Therefore, MV demonstrates considerable het-
erogeneity, as measured by monoclonal antibody reactivities
and nucleotide sequencing (Rota et al., 1998), as do other
RNA viruses. Genotyping studies done in the last 10 years
have indicated that the RNA sequences of the strains of
MV currently circulating have changed considerably from
those isolated earlier. This suggests that measles virus may
still be able to contribute significantly to worldwide mor-
bidity and mortality caused by infectious diseases as it
evolves under the pressure of elimination efforts.
Thus, there may be a need to supplement global immu-
nization with non-toxic treatments that can be used to treat
unexpected outbreak infections quickly and effectively. No
chemotherapeutic agents have yet been approved for treat-
ment of MV infections, although ribavirin has reportedly
been efficacious when administered intravenously and oral-
ly (Gururangan et al., 1990) alone or in combination with
immune serum globulin in patients (Stogner et al., 1993).
To date, no other clinical trials have been done that support
these findings of efficacy; on the contrary, a number of
studies have also been done showing that ribavirin has no
obvious clinical efficacy in MV infections when given as
small-particle aerosol or intravenously (reviewed by Wyde
et al., 2000).
The recent reports of the broad-spectrum antiviral activ-
ity of 5′-noraristeromycin (1) and its enantiomer (Siddiqi et
DL Barnard et al.
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Figure 1. Structures of 5′-norcarbocyclic adenosine analogues
MV Inhibition by 5′-nor carbocyclic adenosine analogues
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Figure 2. Analysis of the antiviral and cytotoxic interactions of ribavirin with compounds 3, 5 and 8.
(a) Antiviral interactions. (b) Cytotoxicity interactions. There was no cytotoxicity detected at any concentration
of compound 8.
a b
3 a d R bavirin
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al., 1993, 1994; Seley et al., 1997) prompted us to explore
related adenosine analogues (Figure 1) as a potential source
of new agents for treating MV. The results of this study are
reported here.
Materials and methods: chemistry
Synthesis of 5’-nor carbocyclic nucleoside 
analogues
The syntheses of the compounds described herein yielded
enantiomerically pure products and were done following the
procedures developed in the Auburn university laboratory,
Ala., USA: Siddiqi et al. (1993) for (–)-(1S,2R,3S,4R) -4-
(6′-amino-9H-purin-9-yl)cyclopentane-1,2,3-triol (1);
Seley et al. (1998) for (+)-(1S,2S,3R,4S)-4-(6′-amino-9′H-
purin-9′-yl)cyclopentane-1,2,3-triol (2); (–)-(1R,2S,3R)-1-
( 6 ′ - a m i n o - 9 ′H - p u r i n - 9 ′ - y l ) - 2 , 3 - d i h y d o x y
cyclopent-4-ene (3); (+)-(1S,2R,3S)-1-(6′-amino-9′H-
purin-9′-yl)cyclopentane-2,3-dihydoxycyclopentane (4);
(–)-(1R,2S,3R)-1-(6′-amino-9′H-purin-9′-yl)cyclopen-
tane-2,3-dihydoxycyclopentane (5); (+)-(1S,2R,3S)-1-(6′-
amino-9′H-purin-9′-yl)-2,3-dihydoxycyclopent-4-ene (6);
Hegde et al. (1998) for (–)-(1R,2R,3R,4S)-4-azido-1-(6′-
amino-9′H-purin-9′-yl)cyclopentane-2,3-diol (7); (–)-
(1R,2R,3R,4S)-4-amino-1-(6′-amino-9′H-purin-9′-
yl)cyclopentane-2,3-diol (8); (+)-(1S,2S,3S,4R)-4-amino-
1-(6′-amino-9′H-purin-9′-yl)cyclopentane-2,3-diol (18);
(–)-(1R,2S,3S,4S)-4-phenylthio-1-(6′-amino-9′H-purin-
9′-yl)cyclopentane-2,3-diol (9) (SR Das personal commu-
nication); (–)-(1R,2S,3S,4S)-4-methylthio-1-(6′-amino-
9′-H-purin-9′-yl)cyclopentane-2,3-diol (10); (–)-(1R,4S)-
4-methylthio-1-(6′-amino-9′-H-purin-9′-yl)cyclopent-2-
ene (11); (+)-(1S,4R)-4-methylthio-1-(6′-amino-9′-H-
purin-9′-yl)cyclopent-2-ene (16); (–)-(1R,2S,3S,4S)-4-
mercapto-1-(6′-amino-9′-H-purin-9′-yl)cyclopentane-
2,3-diol (14), as developed by SR Das (personal 
communication); (+)-(1S,2R,3R,4R)-4-mercapto-1-(6′-
amino-9′-H-purin-9′-yl)cyclopentane-2,3-diol (15); (–)-
(1R,2S,3S,4S)-4-(isobutylthio)-1-(6′-amino-9′H-purin-
9′-yl)cyclopentane-2,3-diol (12), as developed by SR Das
(personal communication); (+)-(1S,2R,3R,4R)-4-
(isobutylthio)-1-(6′-amino-9′H-purin-9′-yl)cyclopentane-
2,3-diol (13); (–)-8-amino-3-[(1′R,2′S,3′R,4′S)-2′,3′,4′-
trihydroxycyclopent-1′-yl]imidazo[4,5-g]-quinazoline (17),
as developed by VP Rajappan (personal communication).
Ribavirin
Ribavirin, used as a positive control, was obtained from ICN
Pharmaceuticals, Costa Mesa, Calif., USA.
Solubilization of Compounds
The 5′-nor-carbocyclic analogues were made soluble in
mixture of methanol:DMSO (50:50) or in DMSO, prior to
dilution in culture medium for antiviral assays. Ribavirin
was soluble in aqueous media.
Materials and methods: virology
Cells and virus
African green monkey kidney cells (CV-1 cells) were
DL Barnard et al.
4 ©2001 International Medical Press
Table 1. Inhibition of strain Chicago-1 measles virus replication in African green monkey kidney (CV-1)
cells by 5′-nor carbocyclic adenosine analogues
Virus yield
reduction Virucidal Cell 
Visual assay Neutral red assay assay assay cytotoxicity*
Lowest virucidal
EC50 IC50 EC50 IC50 EC90 concentration EC50
Compound (µg/ml) (µg/ml) SI (µg/ml) (µg/ml) SI (µg/ml) (µg/ml) (µg/ml)
1 1.0 >1000† >1000 <1.0‡ 550 >550 0.5 ND >100
2 1.0 >100 >100 1.0 75 75 0.2 ND >100
3 1.0 95 95 1.0 70 70 <0.1 ≥0.64 100
4 <0.1 60 >600 <0.1 61 >610 3.0 ND 100
5 <0.1 >100 >1000 <0.1 >100 >1000 0.4 ≥1 100
6 1.0 >100 >100 <0.1 100 >1000 >100 ND 100
7 0.1 >100 >1000 0.5 >100 >200 11.0 ND >100
8 <0.1 >100 >1000 <0.1 >100 >1000 0.1 >100 >100
Ribavirin 25.0 270 11 20.0 196 10 2.0 >1000 33
*Cytotoxicity was determined in actively growing cells by neutral red assay.
†Concentrations higher than those shown were not tested.
‡Concentrations lower than those shown were not tested.
EC50, 50% effective concentration; IC50, 50% cytotoxic dose; EC90, 90% effective concentration; SI, selectivity index; ND, not determined.
MV Inhibition by 5′-nor carbocyclic adenosine analogues
obtained from American Type Culture Collection (ATCC,
Manassas, Va., USA). The cells were grown in minimal
essential medium (MEM, Gibco-BRL, Gaithersburg,
Md., USA) supplemented with 0.1% NaHCO3 and 10%
fetal bovine serum (FBS, Hyclone Laboratories, Logan,
Utah, USA). When performing antiviral assays, serum was
reduced to 2%, and 50 mg/ml gentamicin (Sigma) was
added to the medium.
MV strain CC was obtained from Pennsylvania State
University. The Edmonston wild-type strain was purchased
from ATCC and all other strains were acquired from PA
Rota and JS Rota (Centers for Disease Control, Atlanta
Ga., USA).
For all studies, except for the multiplicity of infection
study, the viral m.o.i. ranged from 0.0005–0.01 for each
virus tested.
Cytopathic effect inhibition assay
The protocol of Barnard et al. (1997a) was used. Test com-
pounds were tested at varying concentrations (seven 1/2
log10 dilutions). Virus was used at a m.o.i. of 0.001–0.010.
Virus and compound were added in equal volumes to near-
confluent cell monolayers in 96 well tissue culture plates.
The m.o.i. used were virus-dependent and chosen for each
strain, such that 100% of the cells in the virus controls
showed cytopathic effects (CPE) within 5–7 days. The
plates were incubated at 37°C until the cells in the virus
control wells showed complete viral CPE as observed by
light microscopy. Each concentration of drug was assayed
for virus inhibition in quadruplicate and for cytotoxicity in
duplicate. Four wells were set aside as uninfected, untreat-
ed cell controls per test and four wells per test compound
received virus in medium only and represented positive
controls for virus replication. A positive control drug, rib-
avirin, was included for each set of compounds tested. For
all CPE-based assays, the 50% effective concentrations
(EC50) were calculated by regression analysis of the means
of the CPE ratings expressed as percentages of untreated,
uninfected controls for each concentration. A neutral red
assay of the same plate was done to verify the results from
the CPE assay spectrophotometrically (see below). The
usual correlation between the two assays has been greater
than 95% (Barnard, 1997a).
Morphological changes resulting from cytotoxicity of a
compound were graded on a scale of 0–5; 5 being defined
as complete cytotoxicity. The 50% cytotoxic doses (IC50)
were calculated by regression analysis, and a selectivity
index (SI) was calculated using the formula: SI=IC50/EC50.
Neutral red uptake assay of CPE inhibition and compound
cytotoxicity
This assay was done on the same CPE inhibition test
plates described above to verify the inhibitory activity and
the cytotoxicity observed by visual observation. The Neutral
red (NR) assay was performed using a modified method of
Cavenaugh et al. (1990) as described by Barnard et al.
(1999). Briefly, medium was removed from each well of a
plate scored for CPE from a CPE inhibition assay, 0.034%
NR in Sörenson’s citrate buffer (pH 4.0) was added to each
well of the plate and the plate incubated for 2 h at 37°C in
the dark. The NR solution was removed from the wells.
After rinsing and aspirating to dryness, the remaining dye
was extracted for 30 min, at room temperature in the dark,
from the cells using absolute ethanol buffered with
Sörenson’s citrate buffer. Absorbances at 540 nm/450 nm
Antiviral Chemistry & Chemotherapy 12:4 5
Table 2. 5′-Nor carbocyclic adenosine analogue not inhibiting strain Chicago-1 measles virus replication in
African green monkey cells (CV-1) kidney
Visual assay Neutral red assay
EC50 IC50 EC50 IC50
Compound (µg/ml) (µg/ml) SI (µg/ml) (µg/ml) SI
9 >100* >100 0 >100 >100 0
10 >100 >100 0 >100 >100 0
11 >100 20 0 >100 15 0
12 100 >100 >1 >100 >100 0
13 >100 >100 0 >100 >100 0
14 >100 100 0 >100 100 0
15 >100 30 0 >100 100 0
16 >100 60 0 >100 70 0
17 100 >100 >1 100 >100 >1
18 >100 40 0 >100 20 0
Ribavirin 25 270 11 20 196 10
*Concentrations higher than those values shown were not tested. EC50, 50% effective concentration; IC50, 50% cytotoxic dose; SI, selectivity
index.
were read with a microplate reader (Bio-Tek EL 1309; Bio-
Tek Instruments, Winooski, Vt., USA). Absorbance values
were expressed as percentages of untreated controls and
EC50, IC50 and SI values were calculated as described above.
Confirmatory virus yield reduction assay
All compounds with SI greater than 10 were evaluated in a
more sensitive assay to confirm the results of the CPE inhi-
bition/NR uptake assays. Infectious virus yields from each
well from a second CPE inhibition assay were determined
as previously described (Barnard et al., 1997b). After CPE
was scored as described above, each plate was frozen at
–80°C and thawed. Sample wells at each compound con-
centration tested were pooled and titred for infectious virus
by CPE assay. The wells were scored for CPE and virus
titres calculated as described by Barnard et al. (1997b).
A 90% reduction in virus yield was then calculated by
regression analysis. This represented a 1 log10 inhibition in
titre compared with untreated virus controls (Barnard et al.,
1997b). SI was calculated by the formula SI=IC50/EC90.
The IC50 was derived from visual observation of cytotoxic-
ity of the same CPE inhibition assay prior to freezing and
harvesting the virus.
Virucidal assay
For compounds showing good antiviral inhibitory activity,
a virucidal test was done to exclude the possibility that the
compounds inhibited the virus by physically inactivating or
disrupting the virion. The method of Barnard et al. (1997b)
was used. Concentrations tested bracketed the concentra-
tion determined to represent the EC50; each concentration
of test compound was assayed in quadruplicate. Surviving
virus was quantified by CPE assay and titres calculated as
described by Barnard et al. (1997b).
Cytotoxicity testing
Cytotoxicity in rapidly dividing cells was evaluated by
determining the total number of cells as reflected by a NR
uptake assay after a 3-day exposure to several concentra-
tions of compound. The method of Barnard et al. (1997b)
was used. To quantitate cell growth after 72 h in the pres-
ence or absence of drug, the plates were then treated as
described above for the NR assay. Absorbance values were
expressed as percentages of untreated controls, and IC50
values were calculated by regression analysis.
Multiplicity of infection assay
This assay was done as described by Barnard et al. (1997a).
Virus (strain Chicago-1) was used to study the inhibition
by selected compounds at different m.o.i. (Table 2).
Compounds at varying concentrations were evaluated as
described above for the CPE inhibition and NR assays in
the presence of virus at a selected m.o.i. EC50 and IC50 val-
ues were determined as previously described.
Cytopathic effect inhibition timing assay
The CPE inhibition assay, used in this part of the study,
was performed as previously described, although the time
that the compound was added to the plates was varied rel-
ative to the time of virus exposure. At the appropriate time
after virus exposure (0, 1, 2, 4, 6, 8, 24 h), varying dilutions
of test compounds in a small volume were added to the cells
without removal of the virus. When a pretreatment was
done (–1 h), compound was added to the wells and incu-
bated for 1 h at 37°C, after which, virus at an appropriate
m.o.i. was added to each well in a small volume. At ‘0’ time,
the virus were added within 5 min of drug addition as
described previously for the CPE inhibition assay (Barnard
et al., 1997a). The EC50, IC50 and SI values were derived
DL Barnard et al.
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Table 3. Inhibition of the replication of various strains of measles virus in African green monkey kidney (CV-1)
cells by 3, 5, 8 and ribavirin
3 5 8 Ribavirin
Visual assay NR assay Visual assay NR assay Visual assay NR assay Visual assay NR assay
EC50 EC50 EC50 EC50 EC50 EC50 EC50 EC50
Virus strain (µg/ml) (µg/ml) (µg/ml) (µg/ml) (µg/ml) (µg/ml) (µg/ml) (µg/ml)
Bil >10* >10 >10 >10 100 100 100 100
CC 0.05 0.05 0.05 0.05 30 10 20 20
Chicago 1 1 <0.1 <0.1 <0.1 <0.1 25 20
TN 1994 0.1 0.1 0.1 0.1 4 0.6 10 10
Edmonston >64 >64 >64 >64 60 40 10 10
Halonen <0.1† <0.1 <0.1 <0.1 0.4 0.2 1 1
SA 50 >100 >100 >100 >100 >100 20 20
X-1108 >100 >100 >10 >10 10 15 20 20
*Concentrations higher than those shown were not tested.
† Concentrations lower than those shown were not tested.
EC50, 50% effective concentration; NR, neutral red.
MV Inhibition by 5′-nor carbocyclic adenosine analogues
from visual and NR assays as described above.
Drug combination assays
Concentrations of test compounds were evaluated alone
and in combination with varying concentrations of rib-
avirin. The following drug concentrations were used when
antiviral interactions were analysed: 3=0.1–100 mg/ml,
5=0.01–100 mg/ml, 8=0.01–100 g/ml, ribavirin=0.1–100
mg/ml. The following drug concentrations were used when
cytotoxic interactions were analysed: 3=0.1–100 mg/ml,
5=0.1–100 mg/ml, 8=0.1–100 mg/ml, ribavirin=1–1000
mg/ml. All combinations, as well as each drug concentra-
tion used alone, were done in quadruplicate in 96-well
microplates. Toxicity controls for each combination were
also run in parallel on the same plate; these consisted of
uninfected cells similarly treated with each drug combina-
tion, as well as each concentration of either drug used
alone. The data from the visual assays were verified by NR
assays, although only the data from the visual assays are
shown in Figure 2.
The evaluation of synergism was done using the 3-
dimensional computerized system of Prichard and
Shipman (1990) with the MacSynergy™ computer pro-
gram. The difference between the observed effects and
those expected if the interactions had occurred independ-
ently, are expressed as synergy volume above and below the
plane that represents no interactive effects. Any peaks
above the plane are indicative of synergy, while any peaks
below the plane are indicative of metabolism.
Results
Primary characterization of antiviral activity
A series of 5′-norcarbocyclic nucleoside analogues were
evaluated for anti-measles virus activity using strain
Chicago-1. Of the compounds tested, eight (compounds
1–8) were found to be active, with selective indices greater
than 10 (Table 1). The EC50 values ranged from <0.1 to
1mg/ml by CPE inhibition assay, as verified by neutral red
assay. Compounds 4, 5, 7 and 8 were the most potent (see
EC50 values). Most of the active compounds were not toxic
at the concentrations used (Table 1). Compounds 9–17
were considered inactive (Table 2). Using a virus yield
reduction assay, compounds 2, 3, 5 and 8 were still found to
potently inhibit MV replication; EC90 values were
≤0.4mg/ml. Further characterization of the antiviral activ-
ity of 3, 5 and 8, revealed that the antiviral activity of two
of the three analogues could not be attributed to the phys-
ical disruption of the virus (Table 1). For example, com-
pound 5, with an EC50 <0.1 mg/ml and an EC90=0.4
mg/ml, was not virucidal at concentrations lower than 1
mg/ml and 8 was not virucidal at any concentration tested.
However, compound 3 probably inhibited virus by both a
virucidal mechanism as well as an antiviral mechanism,
since it inhibited 90% of the virus even at 1 mg/ml. The
antiviral concentrations were EC50=1 mg/ml and EC90 <0.1
mg/ml (Table 1). In addition, none of the active com-
pounds tested were cytotoxic to actively growing CV-1 cells
(Table 1).
Other MV strains
Compound 3 inhibited MV strains CC, TN 1994 and
Halonen (Table 3), but did not inhibit the Bil, and X-1108
strains, and only slightly inhibited Edmonston and SA
strains. However, the three sensitive strains were inhibited
at even lower concentrations of 3 (<0.1 µg/ml compared
with 1 mg/ml versus Chicago-1, Table 1) than strain
Chicago-1, the initial virus used to evaluate antiviral activ-
ity. The inhibition spectrum of compound 5 was nearly
identical to that of compound 3 (Table 3). However, the
5m -nor carbocyclic analogue 8 only potently inhibited
strains Halonen and TN 1994 (Table 3); strain X-1108 was
2–20-fold less sensitive to inhibition compared with strains
Halonen and TN 1994. Strains CC and Edmonston were
Antiviral Chemistry & Chemotherapy 12:4 7
Table 4. Effects of the multiplicity of infection on the inhibition of measles virus Chicago replication in African
green monkey kidney cells (CV-1) by 8 and ribavirin
Compound 8 Ribavirin
Visual assay Neutral red assay Visual assay Neutral red assay
EC50 IC50 EC50 IC50 EC50 IC50 EC50 IC50
m.o.i.* (µg/ml) (µg/ml) SI (µg/ml) (µg/ml) SI (µg/ml) (µg/ml) SI (µg/ml) (µg/ml) SI
0.01 >100† >100 0 >100 >100 0 32 190 6 10 80 8
0.005 100 >100 >1 100 >100 >1 11 190 17 10 210 21
0.002 20 >100 >5 20 >100 >5 10 190 19 10 230 23
0.001† 4.8 >100 >21 3 >100 >33 10 180 18 4.9 100 20
0.0004 <0.1‡ >100 >1000 100 >1000 6 190 32 4 102 51
*m.o.i. for antiviral tests was 0.0005–0.001.
†Concentrations higher than those shown were not tested.
‡Concentrations lower than those shown were not tested.
EC50, 50% effective concentration; IC50, 50% cytotoxic dose; SI, selectivity index.
slightly inhibited by compound 8 and strain SA was not
inhibited at all. The potency of inhibition (EC50) of strain
Halonen by 8 was 0.4 mg/ml by visual CPE inhibition
assay, which was verified by NR assay (EC50=0.2 mg/ml);
for strain TN 1994 the EC50 values were 4 mg/ml and
0.6mg/ml by visual CPE inhibition and NR assay, respec-
tively.
Effects of multiplicity of infection
Analogue 8 was evaluated for the effects of virus concen-
tration on the potency of inhibition. At higher m.o.i., the
compound was not inhibitory to strain Chicago-1 (Table
4). Only at virus/cell ratios below 0.002 did 8 inhibit the
virus strikingly. The positive control drug, ribavirin, also
showed this ‘m.o.i. dependency’.
Preliminary mode of action studies
To understand the potential viral targets of these com-
pounds, times of addition studies were done. When the
times that 3, 5 and 8 were added to virus infected cells were
analysed for potency of inhibition, all three compounds
were very inhibitory for strain Chicago-1 replication, even
up to 24 h post-virus exposure (Table 5). However, of the
three analogues, 5 was the most inhibitory, and consistent-
ly remained so up to and including 24 h post-virus expo-
sure. It could also be used prophylactically at similar con-
centrations to achieve inhibition of virus replication com-
parable to the times when it was added after virus exposure.
Compound 3 was also consistently inhibitory, regardless of
the time of addition. However, the inhibitory activity of 8
began to wane at 8 h post-virus exposure.
Drug combination studies
It was interesting to determine how 3, 5 and 8 would inter-
act with ribavirin when used in combination with that
compound. Therefore, each of these 5′-nor carbocyclic ana-
logues were evaluated for efficacy in inhibiting MV strain
Chicago-1 replication in combination with ribavirin.
Varying concentrations of an analogue were evaluated alone
and in combination with varying concentrations of rib-
avirin. The peaks of synergism or antagonism, as ascer-
tained by the MacSynergy™ computer program, were used
as measure of the effects of the drug combinations.
Compounds 5 and 8 appeared to augment the anti-MV
effects of ribavirin (Figure 2a) especially at lower concen-
trations. Compound 3 seemed to have less of an additive
interaction with ribavirin than either 5 or 8. At lower con-
centrations, compound 8 had a large additive affect on the
antiviral effect of ribavirin. In addition, at higher concen-
trations, 3 and 5 seemed to slightly ameliorate (antagonize)
the cytotoxicity of ribavirin (Figure 2b). Because 8 was not
cytotoxic at the concentrations used when assaying the
combination of 8 and ribavirin, interactions were not
demonstrated in that particular assay.
Discussion
Various acyclic and carbocyclic adenosine analogue, which
apparently target S-adenosylhomocysteine (AdoHcy) have
been reported to inhibit the replication of a variety of virus-
es, including arena-, herpes-, irido-, filo- pox-, rhabdo-,
paramyxo-, and reo- and retro-viruses (De Clercq, 1998).
The recent reports of the broad spectrum antiviral activity
of 5′ -noraristeromycin (1), and the C4′ -epimer of its
enantiomer (2), stimulated interest to further explore the
potential of 5′ -nor carbocyclic nucleosides as potent, non-
toxic antiviral agents (Siddiqi et al., 1993, 1994; Seley et al.,
1997).
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Table 5. The effects of the time of addition of 3, 5 and 8 on measles virus replication in African green monkey
kidney cells (CV-1)
EC50
Time of 3 5 8 Ribavirin
addition of Visual Neutral Visual Neutral Visual Neutral Visual Neutral 
compound assay red assay assay red assay assay red assay assay red assay
–1* 0.5 3 0.01 0.01 0.1 0.2 6 0.6
0† 0.1 0.1 0.01 0.01 0.2 0.4 3 0.3
1‡ 0.2 <0.1§ 0.02 0.01 0.06 0.1 13 5
2 0.5 1 0.02 0.02 0.1 0.18 15 12
4 0.5 3 <0.01 <0.01 0.1 0.1 18 12
6 0.5 3 <0.01 <0.01 0.1 0.09 15 12
8 0.5 1 <0.01 <0.01 1 0.5 18 12
24 0.5 3 0.05 0.03 1 2.6 15 12
*Compound was added to the cells 1 h before exposure to virus. At 0 time, virus was added, at the appropriate m.o.i., to the compound-treat-
ed cells and incubated with the cells until the assay was ended.
†An equal volume of virus was added to dilutions of compound present on cells within 5 min of compound addition to cells.
‡After exposure of cells to virus for one the time periods (1–24 h) indicated, an appropriate concentration was added to the virus-infected cells
and incubated with those cells until the assay ended.
§Concentrations lower than shown were not tested. EC50, 50% effective concentration.
MV Inhibition by 5′-nor carbocyclic adenosine analogues
Some structure activity relationships could be deter-
mined from the data. For example, removal of the C4′
hydroxyl from 5′ -noraristeromycin (1) and from (2) to give
4 and 5 enhanced the MV inhibitory activity by 10–fold, as
detected by CPE inhibition and NR assays as was likewise
reported by Seley et al. (1998) for anti-HBV activity.
Addition of an amine group at the C-5′ position (8)
improved the inhibitory activity as measured by all assays,
but the L-enantiomer (18) was inactive. By contrast, an
azido addition at the same position (7) did not substantial-
ly affect the potency relative to the other compounds.
Additions of sulfur-containing groups at C4′ resulted in
inactive compounds (9-18); this was presumably due to
electronic or steric effects from these constituents.
In our hands 1 showed an antiviral profile similar to that
of Siddiqi et al. (1994). Unlike compound 1, compounds
3–8 apparently are not broad-spectrum inhibitors of virus
replication. Although compounds 3–8 inhibited a number
of MV in this study, those same compounds did not inhib-
it an adenovirus, a flavivirus, an arena virus, a bunya virus,
influenza A viruses, other paramyxoviruses and a rhinovirus
(data not shown). However, compounds 3 and 5 did inhib-
it vaccinia virus and compounds 3–8 inhibited several
influenza B viruses, although at concentrations 4–50-fold
higher than those that inhibited MV replication (data not
shown). Thus, unlike other carbocyclic adenosine ana-
logues, the spectrum of viruses inhibited by these analogues
of 1 is quite limited. This suggests that although the target
of inhibition could be S-adenosylhomocysteine hydrolase
activity, as has been theorized for other carbocyclic adeno-
sine analogues (reviewed by De Clercq, 1998), other targets
of inhibition may be possible. The timing studies show that
compounds 3, 5, and 8 effectively inhibit some target up to
24 h post infection. That could imply that an event occur-
ring late in infection such as assembly or egress could be
inhibited. Alternatively, the compounds might be irre-
versible inhibitors of an earlier replication event.
When three of the active compounds (3, 5, 8) were eval-
uated against other MV strains, the inhibitory activity
demonstrated strain specificity. Strains Bil, Edmonston, SA
and X-1108 were not sensitive to inhibition by any of these
compounds when tested at the concentrations used in the
antiviral assays. The spectrum of MV strains inhibited by
these carbocyclic analogues did not necessarily correlate
with any particular clade system or genetic grouping system
developed for MV (Bellini & Rota, 1998, Rota et al., 1998;
Takeda et al., 1999;). For example, Halonen and
Edmonston are in the group 1 genotype, but the replication
of strain Halonen, a wild-type strain, was extremely sensi-
tive to inhibition by these compounds; Edmonston, a wild-
type strain, replication was not inhibited.
This series of 5′-nor carbocyclic nucleoside analogues are
potent, relatively non-toxic, specific inhibitors of MV repli-
cation. Thus, they represent a new potent class of com-
pounds that may become clinically relevant anti-MV agents
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